A low- versus standard-dose regimen as induction for pediatric AML: a multicenter, randomized noninferiority trial - PubMed
12 hours ago
- #pediatric AML
- #chemotherapy
- #noninferiority trial
- A randomized, multicenter, noninferiority trial compared low-dose chemotherapy (LDC) and standard-dose chemotherapy (SDC) for pediatric AML induction.
- Complete remission rates were similar between LDC (95.1%) and SDC (95.3%) arms.
- Measurable residual disease <0.1% after induction II was comparable (87.4% LDC vs. 87.1% SDC).
- LDC showed faster neutrophil and platelet recovery compared to SDC.
- 4-year overall survival (OS) and event-free survival (EFS) were not significantly different between LDC and SDC.
- LDC was well-tolerated and noninferior to SDC in efficacy and safety outcomes.